Literature DB >> 24604697

Disease pathways in proliferative vitreoretinopathy: an ongoing challenge.

Gian Marco Tosi1, Davide Marigliani, Napoleone Romeo, Paolo Toti.   

Abstract

Despite remarkable advances in vitreoretinal surgery, proliferative vitreoretinopathy (PVR) remains a common cause of severe visual loss or blindness. One of the critical reasons for PVR-induced blindness is tractional retinal detachment due to the formation of contractile preretinal fibrous membranes. This membrane formation is characterized by the proliferation and migration of cells and the excessive synthesis and deposition of extracellular matrix proteins. Herein we present the disease pathways of PVR, reviewing the role of both systemic and intraocular cells as well as molecular mediators. A chronological sequence of events leading to PVR is also hypothesized. Better understanding of the pathogenesis of PVR is needed in order to improve disease management. Efforts should be oriented towards greater cooperation between basic researchers and clinicians, aimed at matching the different clinical scenarios with the biological markers of the disease.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24604697     DOI: 10.1002/jcp.24606

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  31 in total

Review 1.  [Histological diagnostics of enucleated eyes].

Authors:  S Koinzer; K Löffler
Journal:  Pathologe       Date:  2015-07       Impact factor: 1.011

2.  The effects of pleiotrophin in proliferative vitreoretinopathy.

Authors:  Xue Ding; Yujing Bai; Xuemei Zhu; Tianqi Li; Enzhong Jin; Lvzhen Huang; Wenzhen Yu; Mingwei Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-01-12       Impact factor: 3.117

Review 3.  Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis.

Authors:  Daisy Y Shu; Frank J Lovicu
Journal:  Prog Retin Eye Res       Date:  2017-08-12       Impact factor: 21.198

4.  Effects of resveratrol on ARPE-19 cell proliferation and migration via regulating the expression of proliferating cell nuclear antigen, P21, P27 and p38MAPK/MMP-9.

Authors:  Xiao-Ning Hao; Wen-Jie Wang; Jian Chen; Qing Zhou; Yi-Xin Qu; Xiao-Yong Liu; Wei Xu
Journal:  Int J Ophthalmol       Date:  2016-12-18       Impact factor: 1.779

5.  The Peculiar Pattern of Type IV Collagen Deposition in Epiretinal Membranes.

Authors:  Marì Regoli; Gian Marco Tosi; Giovanni Neri; Annalisa Altera; Daniela Orazioli; Eugenio Bertelli
Journal:  J Histochem Cytochem       Date:  2019-12-20       Impact factor: 2.479

6.  Patching retinal breaks with Seprafilm for treating retinal detachments in humans: 9 years of follow-up.

Authors:  M Haruta; M Arai; J Sueda; T Hirose; R Yamakawa
Journal:  Eye (Lond)       Date:  2017-01-27       Impact factor: 3.775

7.  GSK3β inhibits epithelial-mesenchymal transition via the Wnt/β-catenin and PI3K/Akt pathways.

Authors:  Cheng Zhang; Li Su; Li Huang; Zheng-Yu Song
Journal:  Int J Ophthalmol       Date:  2018-07-18       Impact factor: 1.779

8.  Retinal pigment epithelial cell multinucleation in the aging eye - a mechanism to repair damage and maintain homoeostasis.

Authors:  Mei Chen; Dinusha Rajapakse; Monika Fraczek; Chang Luo; John V Forrester; Heping Xu
Journal:  Aging Cell       Date:  2016-02-15       Impact factor: 9.304

9.  Resveratrol inhibits epithelial-mesenchymal transition of retinal pigment epithelium and development of proliferative vitreoretinopathy.

Authors:  Keijiro Ishikawa; Shikun He; Hiroto Terasaki; Hossein Nazari; Huiming Zhang; Christine Spee; Ram Kannan; David R Hinton
Journal:  Sci Rep       Date:  2015-11-10       Impact factor: 4.379

10.  Epithelial Membrane Protein-2 in Human Proliferative Vitreoretinopathy and Epiretinal Membranes.

Authors:  David G Telander; Alfred K Yu; Krisztina I Forward; Shawn A Morales; Lawrence S Morse; Susanna S Park; Lynn K Gordon
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-06-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.